Short Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Drops By 15.2%

Posted by on Jun 17th, 2022

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 338,900 shares, a decrease of 15.2% from the May 15th total of 399,500 shares. Based on an average trading volume of 117,000 shares, the short-interest ratio is presently 2.9 days.

A number of institutional investors have recently modified their holdings of LIFE. Virtu Financial LLC acquired a new stake in shares of aTyr Pharma in the first quarter valued at $70,000. Charles Schwab Investment Management Inc. acquired a new stake in aTyr Pharma in the fourth quarter valued at about $75,000. Qube Research & Technologies Ltd purchased a new stake in aTyr Pharma during the fourth quarter worth about $87,000. Goldman Sachs Group Inc. purchased a new position in aTyr Pharma in the 4th quarter valued at approximately $138,000. Finally, Millennium Management LLC acquired a new stake in aTyr Pharma in the second quarter valued at $148,000. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

LIFE has been the subject of a number of analyst reports. StockNews.com upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, June 9th. Piper Sandler dropped their target price on aTyr Pharma from $19.00 to $11.00 and set an “overweight” rating for the company in a report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.67.

Shares of NASDAQ:LIFE traded up $0.08 during mid-day trading on Friday, reaching $2.71. The stock had a trading volume of 1,353 shares, compared to its average volume of 70,416. The company has a market cap of $76.04 million, a P/E ratio of -1.49 and a beta of 1.56. The business’s 50 day moving average price is $3.59 and its 200 day moving average price is $5.31. aTyr Pharma has a 1 year low of $2.60 and a 1 year high of $13.10.

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.10). During the same quarter last year, the firm posted ($0.51) earnings per share. As a group, equities research analysts anticipate that aTyr Pharma will post -1.75 EPS for the current year.

aTyr Pharma Company Profile (Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.